Lilly Publicizes Webcast to Present Diabetes Portfolio Replace at ADA

0
502

INDIANAPOLIS, June 11, 2021 / PRNewswire / – Eli Lilly and Company (NYSE: LLY) will be webcasting on Thursday 1st July 2021 to discuss the company’s diabetes portfolio and presentations at the American Diabetes Association’s 81st virtual scientific sessions. The webcast starts at 10:00 a.m. Eastern Time and comments will focus on the results of the Tirzepatid SURPASS clinical trial program and the expected next steps for Tirzepatid, as well as Lilly’s once-weekly basal insulin and early-stage incretins in people with diabetes.

Investors, the media and the public can access a live webcast of the conference call via a link posted on Lilly’s website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website after the conference call.

About Eli Lilly and Company
Lilly is a global healthcare leader that combines care with research to create drugs that improve the lives of people around the world. We were founded more than a century ago by a man dedicated to developing high quality medicines that meet real needs, and we remain true to that mission in all of our work today. Around the world, Lilly employees work to discover life changing medicines and bring them to those in need, improve understanding and treatment of disease, and give back to communities through philanthropy and volunteering. To learn more about Lilly, please visit us at www.lilly.com and www.lilly.com/news. F-LLY

Lilly Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about tirzepatide, Lilly’s weekly basal insulin and early-stage incretins, and reflects Lilly’s current beliefs and expectations. As with any pharmaceutical product, however, there are significant risks and uncertainties in the process of research, development and commercialization. Among other things, it cannot be guaranteed that the studies will be completed as planned, that future study results will match previous results, or that drugs will receive regulatory approvals or be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly’s latest Forms 10-K and 10-Q filed with the Securities and Exchange Commission. Except as required by law, Lilly assumes no obligation to update any forward-looking statements to reflect events after the date of this release.

Refer to:
Molly McCully; [email protected]; 317-478-5423 (Media)
Kevin Hern; [email protected]; 317-277-1838 (investors)


SOURCE Eli Lilly and Company

similar links

http://www.lilly.com